Atossa Therapeutics Q4 EPS $(0.03) Beats $(0.07) Estimate

Atossa Therapeutics (NASDAQ: ATOS) reported a Q4 loss of $(0.03) per share, surpassing the analyst consensus estimate of $(0.07) by 55.22%. This represents an 88% improvement compared to losses of $(0.25) per share in the same quarter last year.